Press "Enter" to skip to content

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Also Read:   IIT-Guwahati, RR Animal Healthcare make headway in indigenous Covid-19 kits commercialisation